Granted Patent
B2
US 12,746,225 · App. 19/382,043 · Granted Sep 29, 2026
Methods of treating fibrotic liver diseases or conditions with indeglitazar
Assignee:
PLEIOGENIX INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods of treating alcoholic hepatitis in a subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.
Claims (12)
1 . A method of treating a fibrotic liver disease or fibrotic liver condition in a subject, comprising administering to the subject a therapeutically effective amount of indeglitazar or a pharmaceutically acceptable salt thereof.
2 . The method of the claim 1 , wherein the subject does not have type 2 diabetes.
3 . The method of claim 1 , wherein the subject has type 2 diabetes.
4 . The method of claim 1 , wherein the subject has an F2 or F3 grade fibrosis using the NASH Clinical Research Network (CRN) fibrosis score.
5 . The method of claim 1 , wherein the subject has an AST level greater than the upper limit of normal.
6 . The method of claim 1 , wherein the subject has an ALT level greater than the upper limit of normal.
7 . The method of claim 1 , wherein the subject has an ALP level greater than the upper limit of normal.
8 . The method of claim 1 , wherein:
a) the amount of administered indeglitazar or a pharmaceutically acceptable salt thereof, is from about 20 mg/day to about 225 mg/day; and
b) the indeglitazar or a pharmaceutically acceptable salt thereof, is administered orally.
9 . The method of claim 1 , wherein indeglitazar or the pharmaceutically acceptable salt thereof is administered orally.
10 . The method of claim 1 , wherein the subject is administered one or more additional therapeutically active agents, selected from resmetirom, glucagon-like peptide-1 (GLP-1) receptor agonists, GLP-1 and gastric inhibitory polypeptide (GIP) receptor dual agonists, or GLP-1, GIP, and glucagon receptor triple agonists.
Continuity (5)
Provisional Application
63526840
· Jul 14, 2023
Provisional Application
63532001
· Aug 10, 2023
References Cited (57)
US 7202266B2
· Arnold
· 2007
[cited by applicant]
US 20060252670A1
· Fiorucci
· 2006
[cited by applicant]
US 20070072904A1
· Lin
· 2007
[cited by applicant]
US 20200000772A1
· Lefebvre
· 2020
[cited by applicant]
US 20250319066A1
· Manchem et al.
· 2025
[cited by applicant]
CN 115504925A
· 2022
[cited by applicant]
EP 2990037A1
· 2016
[cited by applicant]
WO 2005009958A1
· 2005
[cited by applicant]
Artis et al (Year: 2009).
[cited by examiner]
Devchand PR et al., The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond, Front Pharmacol, (2018), 9:1093.
[cited by applicant]
Du J et al., Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis, World J Gastroenterol, (2014), 20:569-77.
[cited by applicant]
He L et al., Heart Failure Carnitine Palmitoyltransferase-1b Deficiency Aggravates Pressure Overload—Induced Cardiac Hypertrophy Caused by Lipotoxicity, Circulation, (2012), 126:1705-16.
[cited by applicant]
Lamas-Paz et al., Alcoholic liver disease: Utility of animal models, World J Gastroenterol, (2018), 24:5063-75.
[cited by applicant]
Louvet et al., Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor, Gastroenterology, (2009), 137:541-8).
[cited by applicant]
Lucey et al., Alcoholic Hepatitis, N Engl J Med, (2009), 360:2758-69.
[cited by applicant]
Mathurin et al., Early Liver Transplantation for Severe Alcoholic Hepatitis, N Engl J Med, (2011), 365:1790-800.
[cited by applicant]
Moreau et al., Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis, Gastroenterology, (2013), 144:1426-37, 37 e1-9.
[cited by applicant]
Nesto et al., Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure, Circulation, (2003), 108:2941-8.
[cited by applicant]
Pouwels et al., on-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss, BMC Endocr Disord, (2022), 22:63.
[cited by applicant]
Rao et al.,Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease, Am J Physiol Gastrointest Liver Physiol, (2004), 286:G881-4.
[cited by applicant]
Saha et al.,Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis, Hepatology, (2019), 70:1134-49.
[cited by applicant]
Sanyal et al., Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, N Engl J Med, (2010), 362:1675-85.
[cited by applicant]
Shah et al., Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice, Oxid Med Cell Longev, (2018), p. 1-2, 2018:9630175.
[cited by applicant]
Szabo et al., Gut-liver axis and sterile signals in the development of alcoholic liver disease, Alcohol Alcohol, (2017), 52:414-24.
[cited by applicant]
Tasdogan et al., Update on Immunosuppression in Liver TransplantatioN, Euroasian J Hepatogastroenterol, (2019), 9:96-101.
[cited by applicant]
Thompson et al., Mortality and costs associated with alcoholic hepatitis: A claims analysis of a commercially insured population, Alcohol, (2018), 71:57-63.
[cited by applicant]
Thursz et al., he clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial, Health Technol Assess, (2015), 19:1-104.
[cited by applicant]
Tilg et al., Interleukin-1 and Inflammasomes in Alcoholic Liver Disease/Acute Alcoholic Hepatitis and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Hepatology, (2016), 64:955-65.
[cited by applicant]
Gul, et al., Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations, Plos One, (2023), p. 1-35.
[cited by applicant]
Francque, et al., A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH, New England Journal of Medicine, (2021), 385:1547-1558.
[cited by applicant]
Pawlak, et al., Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, Journal of Hepatology, (2015), 62:720-733.
[cited by applicant]
Barbosa-Da-Silva, et al., Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice, Life Sciences, (2015), 127:73-81.
[cited by applicant]
Chen et al., Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists, Bioorganic & Medicinal Chemistry, (2023), 96:117533, p. 1-12.
[cited by applicant]
Cheng et al., Exploration and Development of PPAR modulators in Health and Disease: An Update of Clinical Evidence. Int. J. Mol. Sci., (2019), 20:5055, p. 1-50.
[cited by applicant]
Dolgin, Nash therapies head toward landmark approval, Nature Biotechnology, (2023), 41:587-590.
[cited by applicant]
Kersten et al., The role and regulation of the peroxisome proliferator activated receptor alpha in human liver, Biochimie, (2017), 136:75-84.
[cited by applicant]
International Search Report from Appl. No. PCT/US2024/037827, mail on Sep. 19, 2024.
[cited by applicant]
Artis et al., Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent, PNAS, (2009), 106:262-267.
[cited by applicant]
Sheka et al., Nonalcoholic Steatohepatitis, JAMA, (2020), 323:1175-1183.
[cited by applicant]
Barrio et al., Liver Disease in Heavy Drinkers With and Without Alcohol Withdrawal Syndrome, Alcohol Clin Exp Res, (2004), 28:131-136.
[cited by applicant]
Bataller et al., Alcohol-Associated Hepatitis, N Engl J Med, (2022), 387:2436-48.
[cited by applicant]
Betteridge et al., Diabet. Med., (2011), 28:759-771.
[cited by applicant]
Crews et at., Cytokines and Alcohol, Alcohol Clin Exp Res, (2006), 30: 720-730.
[cited by applicant]
Kleiner et al., Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease, Hepatology, (2005), 41:1313-1321.
[cited by applicant]
Morgan et al., Pentoxifylline and Alcoholic Hepatitis, Gastroenterology, (2000), 119: 1787-1790.
[cited by applicant]
Yasir et al., Corticosteroid Adverse Effects, StatPearls. Treasure Island (FL): StatPearls PublishingCopyright © 2023, StatPearls Publishing LLC., (2023).
[cited by applicant]
NCT00448032, Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects, (2007).
[cited by applicant]
NCT00425919, Study Evaluating PPM-204 In Subjects With Type 2 Diabetes, (2007).
[cited by applicant]
Jusudian et al., Acute alcoholic hepatitis as indication for liver transplantation, Curr Opin Organ Transplant, (2016), 21:107-10.
[cited by applicant]
Mudaliar et al., Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications, Endocr Pract, (2003), 9:406-16.
[cited by applicant]
James O'Beirne J., Readmission Following Hospitalization for Alcoholic Hepatitis: Costly or Cost-Effective?, Dig Dis Sci., (2020), 65:920-1.
[cited by applicant]
Son et al., Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice, J Clin Invest, (2007), 117:2791-801.
[cited by applicant]